Literature summary for 4.3.2.1 extracted from

Huang, H.L.; Chen, W.C.; Hsu, H.P.; Cho, C.Y.; Hung, Y.H.; Wang, C.Y.; Lai, M.D.
Argininosuccinate lyase is a potential therapeutic target in breast cancer (2015), Oncol. Rep., 34, 3131-3139 .

Search for more literature for 4.3.2.1

Application

Application	Comment	Organism
drug development	argininosuccinate lyase (ASL) is overexpressed in breast cancer and downregulation of argininosuccinate lyase decreases tumor growth by inhibiting cyclin A2 and NO. Administration of ASL shRNA may be a treatment to prevent cancer cell proliferation and induce cancer cell death	Homo sapiens
medicine	argininosuccinate lyase (ASL) is overexpressed in breast cancer and downregulation of argininosuccinate lyase decreases tumor growth by inhibiting cyclin A2 and NO. Administration of ASL shRNA may be a treatment to prevent cancer cell proliferation and induce cancer cell death	Homo sapiens
pharmacology	argininosuccinate lyase (ASL) is overexpressed in breast cancer and downregulation of argininosuccinate lyase decreases tumor growth by inhibiting cyclin A2 and NO. Administration of ASL shRNA may be a treatment to prevent cancer cell proliferation and induce cancer cell death	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	P04424	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
breast cancer cell	the enzynme is overexpressed in breast cancer	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
ASL	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)